Clinical trial · Interventional
Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
NCT00029328CI-TRIAL-00017249completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the effects of etanercept, and define the toxicity, when administered to patients with acute non-infectious lung injury (idiopathic pneumonia syndrome, IPS) and with subacute pulmonary dysfunction after allogeneic stem cell transplantation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bronchiolitis Obliterans | — | UNRESOLVED | — |
| Pneumonia | — | UNRESOLVED | — |
| Respiratory Distress Syndrome, Adult | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| etanercept | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Months
Show eligibility criteria text
Inclusion criteria: * Diagnosis of acute idiopathic pneumonia syndrome (IPS) or sub-acute lung injury * At least 1 year of age for IPS stratum * At least 6 years of age for sub-acute lung injury stratum and able to perform formal pulmonary function testing * At least 14 days since prior treatment with an investigational drug for graft-versus-host disease * Previously treated with allogeneic stem cell or bone marrow transplantation for primary disease Exclusion criteria: * Documented evidence of active systemic or pulmonary infection * Cardiogenic failure as cause of pulmonary dysfunction * Known hypersensitivity to etanercept * Currently receiving dialysis * Currently receiving inotropic medications except dopamine * Pregnant or nursing
References
Publications (0)
Data not yet available
No reference posted for this study.